Variant and Molecular Result Ingestion
Receiving results from sequencing laboratories in varied formats, storing variants discretely with the assay and coverage context needed to interpret them.
Custom Software
Hire Precision Medicine Engineers
Precision medicine engineers build systems that organize molecular results and evidence for clinical interpretation. They handle variant data ingestion, knowledge base curation, evidence tiering, and molecular tumor board workflow, working so clinicians and interpretation committees make every determination about clinical significance and therapy.
The defining difficulty is that evidence changes faster than software. A variant classified as uncertain today may be reclassified next year, and a therapy association may be strengthened or withdrawn. Systems that embed interpretation as fixed logic become confidently outdated. The engineering answer is curated, versioned evidence with reinterpretation workflow. Taction Software builds for that, and our hire dedicated developers hub covers adjacent roles.
Tell Us Your Requirements
Our experts are ready to understand your business goals.
Trusted Partners
Trusted by Industry Leaders Worldwide
Recognition
Awards & Recognitions
What Precision Medicine Engineers Build
The work centers on organizing molecular information so an interpretation committee can reach a decision efficiently, and on making earlier decisions revisitable when evidence changes. The work below reflects that. Note the emphasis on reinterpretation and provenance, because a variant classified two years ago under different evidence is a clinical liability if nobody can identify which patients are affected.
Evidence Knowledge Base Curation
Maintaining curated associations between molecular findings, evidence levels, and therapeutic or prognostic implications, with sources and versions recorded.
Evidence Tiering and Presentation
Organizing findings by evidence strength using established tiering frameworks, so a committee sees what is well supported separately from what is speculative.
Molecular Tumor Board Workflow
Assembling case packets with molecular results, relevant evidence, prior therapy, and trial options, and recording the committee’s determination and reasoning.
Reinterpretation and Reclassification Tracking
Identifying which patients are affected when a variant classification or evidence association changes, and routing them for reconsideration.
Trial and Therapy Option Surfacing
Presenting therapy options and trial opportunities associated with findings, as candidates for committee consideration rather than as treatment recommendations.
Molecular and Clinical Context This Role Requires
Precision medicine operates on evolving evidence with substantial uncertainty, and the systems must represent that uncertainty rather than resolving it. Variants of uncertain significance are common, evidence quality varies enormously, and associations established in one tumor type may not transfer to another. Engineers must build for ambiguity. The context below spans the healthcare work you assign.
01
Uncertainty Is the Normal State
Many findings have uncertain significance. Systems must display that clearly rather than presenting the strongest available association as if it were established.
02
Evidence Tiers Are Not Interchangeable
An association from a case report differs from one from a randomized trial. Presentation must preserve that distinction, since committees weight them very differently.
03
Reclassification Creates Retrospective Obligations
When a variant is reclassified, previously interpreted patients may need reconsideration. Systems without reinterpretation tracking cannot identify who is affected.
04
Tumor Type Context Governs Transferability
A therapy association established in one cancer type does not automatically apply to another. Presenting cross-indication associations without that context misleads.
05
Assay Coverage Limits Conclusions
A negative result reflects only what the assay examined. Coverage detail must accompany results, since absence of a finding is frequently misread as absence of the variant.
06
Committees and Clinicians Determine Therapy
Systems organize evidence. Determination of clinical significance and treatment selection belong to the molecular tumor board and treating clinician.
Technical Skills for Precision Medicine Systems
This work is data modeling, knowledge management, and workflow engineering. The bioinformatics is usually upstream at the laboratory; the system’s job is representing results and evidence faithfully with full provenance. The competencies below reflect that. Weight knowledge base versioning and provenance above analytical capability, since the durable value is a system whose past decisions remain explicable and revisitable.
Variant Data Modeling With Provenance
Storing variants, assay context, coverage, and interpretation history discretely, so any past interpretation can be reconstructed with the evidence available at the time.
Knowledge Base Curation Infrastructure
Managing evidence associations with sources, tiers, versions, and effective dates, supporting curators rather than embedding associations in application logic.
Evidence Tiering Implementation
Applying established tiering frameworks consistently, with the framework and version recorded, since tiering conventions differ and have themselves been revised.
Reinterpretation Cohort Identification
Querying which patients carry a reclassified finding and routing them for reconsideration, which is the capability most implementations lack entirely.
Laboratory and Clinical System Integration
Ingesting molecular results and writing committee determinations into the record. Our healthcare integration work covers this connectivity.
Committee Workflow and Decision Capture
Supporting case preparation, discussion, and documented determination with the audit trail clinical governance and future reinterpretation require.
How We Evaluate Precision Medicine Engineers
The distinguishing question is how they handled reclassification. Engineers who built reinterpretation tracking understood that molecular interpretation has retrospective obligations. Our assessment centers on provenance, knowledge versioning, and uncertainty representation. We also probe whether they embedded evidence in code, which produces systems that cannot be updated without redeployment. Our delivery process includes review points.
Reclassification Handling
We ask what happened when a variant was reclassified. Systems without cohort identification cannot tell which patients were interpreted under withdrawn evidence.
Evidence Storage Architecture
We ask where associations lived. Evidence embedded in application logic requires engineering work for every curation change, which means it stops being updated.
Uncertainty Presentation Design
We ask how variants of uncertain significance appeared. Systems presenting the strongest association available misrepresent the state of evidence to committees.
Provenance Reconstruction
We ask whether a past interpretation could be reproduced. Without evidence versioning, nobody can explain why a determination was made two years ago.
Tumor Type Context Handling
We ask how cross-indication associations were presented. Systems omitting indication context suggest transferability the evidence does not support.
Verified Molecular Systems Experience
We describe which precision medicine systems each engineer built and what supported real committees. We do not claim clinical or genomic credentials for engineers.
Engagement Options for Precision Medicine Programs
Engagements should start with result storage and committee workflow rather than with knowledge curation, because organizing what you already have delivers value while curation is a continuing commitment requiring dedicated expertise. Structures below reflect that. We also assess whether commercial knowledge bases would serve, since maintaining curation independently is a substantial ongoing obligation.
Result Storage and Committee Workflow First
Structuring molecular results and supporting the tumor board process delivers value immediately, without committing to independent evidence curation.
Integration of a Commercial Knowledge Base
Curated evidence resources exist. Integrating one is usually preferable to maintaining independent curation, which requires dedicated scientific staffing indefinitely.
A Single Engineer With Committee Input
Suits one program with defined result sources and an active tumor board. Committee input determines whether case packets are usable in practice.
Augmenting Your Genomic Informatics Team
Where you own curation and interpretation practice, staff augmentation adds engineering capacity working within your existing frameworks and governance.
Full Team for Precision Medicine Programs
A dedicated healthcare development team suits programs spanning ingestion, knowledge management, committee workflow, reinterpretation, and clinical record integration.
Fixed-Scope Ingestion and Workflow Build
Where result sources and committee process are defined, a fixed-scope build under our engagement models delivers ingestion, storage, and case preparation.
Tell Us How Your Tumor Board Works Today
Share your molecular result sources, committee process, and whether you curate evidence internally. Curation is a continuing commitment worth examining before building around it.
Uncertainty Representation, Committee Authority, and Boundaries
Precision medicine systems present evidence about therapy where the evidence is frequently limited. Where intended use may create diagnostic or treatment claims, SaMD classification is assessed during discovery. Taction holds no FDA clearance. We build to HIPAA-aligned practices where HIPAA applies; software cannot be HIPAA certified. Genomic data carries additional protections including implications for family members.
01
Committees and Clinicians Determine Therapy
Systems organize and present. Determination of clinical significance, therapy selection, and trial referral belong to the molecular tumor board and treating clinician.
02
Evidence Tier Always Visible
Every association appears with its evidence level and source, so a committee weights a case report differently from a trial result rather than seeing an undifferentiated list.
03
Uncertainty Displayed, Not Resolved
Variants of uncertain significance are presented as uncertain. Systems must not surface the strongest speculative association as though it were established guidance.
04
Assay Coverage Accompanies Results
What the assay examined appears with the result, since a negative finding on an untested region is not evidence the variant is absent.
05
Genomic Data Sensitivity
Molecular results carry implications for relatives and for insurance and employment contexts. Access controls and disclosure handling reflect that beyond ordinary clinical data.
06
Applications We Would Not Build
We would not build systems that recommend therapy autonomously, present speculative associations as established, determine trial eligibility without investigator review, or omit evidence tiering.
Cost to Hire Engineers and Build Precision Medicine Capability
Cost concentrates in result ingestion, provenance modeling, and committee workflow rather than in analysis. Independent knowledge curation, if you choose it, is a continuing scientific staffing cost rather than an engineering line. We publish no figures on therapy selection or outcomes, because those depend on your population, evidence access, and committee practice. What we deliver is provenance and reinterpretation capability.
MVP or Single Module
$40,000 to $80,000
Molecular result ingestion with discrete storage, provenance, evidence tier presentation, and tumor board case preparation workflow for one program.
Full Platform Build
$80,000 to $200,000
Precision medicine capability with multi-source ingestion, knowledge base integration, evidence versioning, reinterpretation cohort identification, committee workflow, and record integration.
Enterprise Deployment
Starting at $200,000
Multi-site deployment across clinical environments with governance documentation, curation infrastructure, and integration into several systems. Cost scales with sources and sites.
Discovery Phase Scoping
Discovery is paid and time-boxed. It produces a result source assessment, curation approach recommendation, committee workflow review, provenance requirements, and an itemized fixed-scope estimate.
Cost Drivers to Expect
Molecular result source count and format variety, knowledge base approach, evidence versioning requirements, reinterpretation scope, committee workflow complexity, and clinical record integration.
Ongoing Support Costs
Evidence changes continuously. Budget for knowledge base updates or subscription, reinterpretation cycles when classifications change, ingestion maintenance, and provenance storage growth.
Third-party licensing, cloud infrastructure, data subscriptions, and hardware are separate from engineering cost and itemised clearly.
Why Build Precision Medicine Capability With Taction
Two questions matter. Whether the vendor builds reinterpretation capability, and whether they will recommend a commercial knowledge base over independent curation. Taction Software has built healthcare software since 2013, more than twelve years, with over 200 healthcare projects delivered and ISO 27001 certification. Leadership brings more than twenty years of personal experience in the field, which is separate from company age. Our wider case for Taction sits elsewhere.
Clinical Data Modeling Depth
We built Voyant Health, an EHR platform. Our healthcare case studies reflect experience modeling clinical data with the provenance long-term interpretation requires.
Sensitive Data Segmentation Experience
We built CHIPSS, a behavioral health system, where access segmentation governed visibility. Genomic data requires comparable and arguably stronger controls.
Experience Under Regulatory Registration
We built Revive Ease and PainKare, both FDA-registered applications. That work informs how we document intended use where systems present therapy-relevant evidence.
ISO 27001 Certified Security Management
Taction Software holds ISO 27001 certification covering our information security management practices. It certifies our internal processes and does not determine your organization’s compliance position.
We Build Reinterpretation Capability
Identifying patients affected by a reclassification is the capability most implementations lack and the one that carries genuine clinical obligation. We build it from the start.
We Will Recommend Buying Curation
Maintaining independent evidence curation requires dedicated scientific staffing indefinitely. Recommending a commercial resource removes a substantial ongoing burden and reduces our scope.
FAQs
Frequently Asked Questions
We review your molecular result sources, committee process, and curation approach, then present candidates with molecular informatics experience. You interview and approve each engineer.
Ingestion with committee workflow runs $40,000 to $80,000, full capability $80,000 to $200,000, and multi-site deployment starts at $200,000. Knowledge base subscriptions and cloud are itemized separately.
Our delivery history includes the Voyant Health EHR platform, the CHIPSS behavioral health system, and the FDA-registered applications Revive Ease and PainKare, within more than 200 healthcare projects delivered since 2013.
The system identifies which patients carry the finding and routes them for reconsideration, and past interpretations remain reconstructable with the evidence available at the time.
No. It organizes molecular findings and tiered evidence for the molecular tumor board. Determination of significance and therapy selection remain with the committee and treating clinician.
Usually subscribe. Independent curation requires dedicated scientific staffing indefinitely, and commercial resources maintain associations more comprehensively than most programs can sustain.
Share your result sources and formats, your tumor board process, your curation approach, your record integration needs, and the engagement model you have in mind. We will prioritize provenance and reinterpretation capability and recommend subscribing to curation where that fits. We do not promise instant matching or any outcome figure.